Publications 2017

Crossley DA, Crossley JL, Smith C, Harfush M, Sánchez-Sánchez H, Garduño-Paz MV, Méndez-Sánchez JF (2017)
Developmental cardiovascular physiology of the olive ridley sea turtle (Lepidochelys olivacea)
Comp Biochem Physiol A Mol Integr Physiol, 211, 69-76
DOI 10.1016/j.cbpa.2017.06.010, PubMed 28642099

Parker SL, Guerra Valero YC, Lipman J, Weiss S, Smith C, Russell L, Smith P, Roberts JA, Wallis SC (2017)
A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples
Biomed Chromatogr, 31 (12)
DOI 10.1002/bmc.4030, PubMed 28623867

Publications 2012

Ueland T, Aukrust P, Aakhus S, Smith C, Endresen K, Birkeland KI, Gullestad L, Johansen OE (2012)
Activin A and cardiovascular disease in type 2 diabetes mellitus
Diab Vasc Dis Res, 9 (3), 234-7
DOI 10.1177/1479164111431171, PubMed 22234949

Publications 2011

Andersen GØ, Ueland T, Knudsen EC, Scholz H, Yndestad A, Sahraoui A, Smith C, Lekva T, Otterdal K, Halvorsen B, Seljeflot I, Aukrust P (2011)
Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation
Diabetes, 60 (5), 1544-51
DOI 10.2337/db10-1493, PubMed 21464440

Publications 2009

Halvorsen B, Heggen E, Ueland T, Smith C, Sandberg WJ, Damås JK, Otterdal K, Tonstad S, Aukrust P (2009)
Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome
Eur J Endocrinol, 162 (2), 267-73
DOI 10.1530/EJE-09-0706, PubMed 19926782

Jansson AM, Aukrust P, Ueland T, Smith C, Omland T, Hartford M, Caidahl K (2009)
Soluble CXCL16 predicts long-term mortality in acute coronary syndromes
Circulation, 119 (25), 3181-8
DOI 10.1161/CIRCULATIONAHA.108.806877, PubMed 19528340

Yndestad A, Larsen KO, Oie E, Ueland T, Smith C, Halvorsen B, Sjaastad I, Skjønsberg OH, Pedersen TM, Anfinsen OG, Damås JK, Christensen G, Aukrust P, Andreassen AK (2009)
Elevated levels of activin A in clinical and experimental pulmonary hypertension
J Appl Physiol (1985), 106 (4), 1356-64
DOI 10.1152/japplphysiol.90719.2008, PubMed 19196915

Publications 2008

Aukrust P, Otterdal K, Yndestad A, Sandberg WJ, Smith C, Ueland T, Øie E, Damås JK, Gullestad L, Halvorsen B (2008)
The complex role of T-cell-based immunity in atherosclerosis
Curr Atheroscler Rep, 10 (3), 236-43
DOI 10.1007/s11883-008-0037-8, PubMed 18489852

Breland UM, Halvorsen B, Hol J, Øie E, Paulsson-Berne G, Yndestad A, Smith C, Otterdal K, Hedin U, Waehre T, Sandberg WJ, Frøland SS, Haraldsen G, Gullestad L, Damås JK, Hansson GK, Aukrust P (2008)
A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins
Arterioscler Thromb Vasc Biol, 28 (5), 1005-11
DOI 10.1161/ATVBAHA.108.162305, PubMed 18276907

Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K (2008)
Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes
J Am Coll Cardiol, 51 (6), 627-33
DOI 10.1016/j.jacc.2007.09.058, PubMed 18261681

Sandberg WJ, Halvorsen B, Yndestad A, Smith C, Otterdal K, Brosstad FR, Frøland SS, Olofsson PS, Damås JK, Gullestad L, Hansson GK, Oie E, Aukrust P (2008)
Inflammatory interaction between LIGHT and proteinase-activated receptor-2 in endothelial cells: potential role in atherogenesis
Circ Res, 104 (1), 60-8
DOI 10.1161/CIRCRESAHA.108.188078, PubMed 19023130

Smith C (2008)
Immunopathogenic mechanisms of coronary artery disease and plaque destabilization
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 599, 1 b. (flere pag.)
BIBSYS 08029877x, ISBN 978-82-8072-725-1

Smith C, Halvorsen B, Otterdal K, Waehre T, Yndestad A, Fevang B, Sandberg WJ, Breland UM, Frøland SS, Oie E, Gullestad L, Damås JK, Aukrust P (2008)
High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins
Cardiovasc Res, 79 (1), 195-203
DOI 10.1093/cvr/cvn071, PubMed 18339644

Publications 2007

Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damås JK (2007)
Chemokines in cardiovascular risk prediction
Thromb Haemost, 97 (5), 748-54
DOI 10.1160/TH07-01-0029, PubMed 17479185

Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P, Halvorsen B (2007)
Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization
Circulation, 115 (8), 972-80
DOI 10.1161/CIRCULATIONAHA.106.665893, PubMed 17283255

Publications 2006

Damås JK, Smith C, Øie E, Fevang B, Halvorsen B, Waehre T, Boullier A, Breland U, Yndestad A, Ovchinnikova O, Robertson AK, Sandberg WJ, Kjekshus J, Taskén K, Frøland SS, Gullestad L, Hansson GK, Quehenberger O, Aukrust P (2006)
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization
Arterioscler Thromb Vasc Biol, 27 (3), 614-20
DOI 10.1161/01.ATV.0000255581.38523.7c, PubMed 17170367

Otterdal K, Smith C, Oie E, Pedersen TM, Yndestad A, Stang E, Endresen K, Solum NO, Aukrust P, Damås JK (2006)
Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes
Blood, 108 (3), 928-35
DOI 10.1182/blood-2005-09-010629, PubMed 16861346

Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P (2006)
Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization
Arterioscler Thromb Vasc Biol, 26 (4), 857-63
DOI 10.1161/01.ATV.0000204334.48195.6a, PubMed 16424351

Smith C, Damås JK, Otterdal K, Øie E, Sandberg WJ, Yndestad A, Waehre T, Scholz H, Endresen K, Olofsson PS, Halvorsen B, Gullestad L, Frøland SS, Hansson GK, Aukrust P (2006)
Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation
J Am Coll Cardiol, 48 (8), 1591-9
DOI 10.1016/j.jacc.2006.06.060, PubMed 17045893

Publications 2005

Aukrust P, Yndestad A, Smith C, Sandberg WJ, Ueland T, Waehre T, Halvorsen B, Gullestad L, Damås JK (2005)
Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation
Expert Opin Pharmacother, 6 (13), 2169-80
DOI 10.1517/14656566.6.13.2169, PubMed 16218879

Damås JK, Boullier A, Waehre T, Smith C, Sandberg WJ, Green S, Aukrust P, Quehenberger O (2005)
Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy
Arterioscler Thromb Vasc Biol, 25 (12), 2567-72
DOI 10.1161/01.ATV.0000190672.36490.7b, PubMed 16224053

Scholz H, Sandberg W, Damås JK, Smith C, Andreassen AK, Gullestad L, Frøland SS, Yndestad A, Aukrust P, Halvorsen B (2005)
Enhanced plasma levels of LIGHT in unstable angina: possible pathogenic role in foam cell formation and thrombosis
Circulation, 112 (14), 2121-9
DOI 10.1161/CIRCULATIONAHA.105.544676, PubMed 16186421

Publications 2004

Smith C, Yndestad A, Halvorsen B, Ueland T, Waehre T, Otterdal K, Scholz H, Endresen K, Gullestad L, Frøland SS, Damås JK, Aukrust P (2004)
Potential anti-inflammatory role of activin A in acute coronary syndromes
J Am Coll Cardiol, 44 (2), 369-75
DOI 10.1016/j.jacc.2004.03.069, PubMed 15261933

Waehre T, Damås JK, Yndestad A, Taskén K, Pedersen TM, Smith C, Halvorsen B, Frøland SS, Solum NO, Aukrust P (2004)
Effect of activated platelets on expression of cytokines in peripheral blood mononuclear cells - potential role of prostaglandin E2
Thromb Haemost, 92 (6), 1358-67
DOI 10.1160/TH04-03-0146, PubMed 15583745

Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, Frøland SS, Semb AG, Aukrust P, Damås JK (2004)
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors
Circulation, 109 (16), 1966-72
DOI 10.1161/01.CIR.0000125700.33637.B1, PubMed 15051633